Middle East Pharmaceutical Industries Company — Cyborg Score 6/10
Solid
Pharmaceutical Manufacturing & Generic Medicines
Strategic Profile
The company operates three factories in Riyadh equipped with production and manufacturing lines for creams, cosmetics, liquid and solid medicines, and disinfectants. Avalon Pharma has a wholly owned subsidiary in the UK, Avalon Pharma UK Holdings Limited, which owns three subsidiaries, demonstrating international growth ambitions. The company leverages vertical integration across manufacturing and distribution to address regional healthcare needs in underserved therapeutic categories.
Cyborg Score Rationale
Avalon benefits from established manufacturing infrastructure, diversified product portfolio, and recent capital market access through IPO. However, as a newly listed entity in a competitive pharmaceutical market with limited recent financial data and operating primarily in generic medicines, execution risks remain. Regional exposure provides growth opportunities but also geopolitical concentration risk.
Top Insights
Recent Tadawul IPO (Feb 2024) at SAR 82/share valued company at SAR 1.64B, with institutional capital access enabling expansion
Diversified therapeutic portfolio across 70+ brands covering skin, respiratory, cardiovascular, diabetes, and antiseptic segments with strong SKU depth (250+ products)
Three vertically integrated manufacturing facilities in Riyadh with modern production lines and quality control capabilities supporting gross margin protection
International footprint through UK subsidiary with three holdings; 0.02% stake in Canadian-listed Columbia Care Inc. signals capital allocation toward healthcare ecosystem expansion
Named Competitors
Generic Medicines & Skincare Products — Leading Saudi pharmaceutical manufacturer with diversified portfolio
Pharmaceutical Manufacturing — Major regional pharmacy and medicine distributor
Healthcare Services — Integrated healthcare provider with pharmaceutical distribution
Recent Developments
(February 2024) IPO listing on Saudi Exchange TADAWUL under ticker 4016, floating 30% of issued share capital (6M shares @ SAR 82/share)
(2022) Converted to closed joint stock company; built new warehouse facility (Avalon Warehouse 4) and converted Warehouse 2 into production facility
(2021) Acquired 0.02% minority stake in Columbia Care Inc., Canadian-listed medical pharmaceutical manufacturer
Open the full interactive Middle East Pharmaceutical Industries Company report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.